Title : Investigation of the Impact of CYP3A5 Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling.

Pub. Date : 2021 Feb 27

PMID : 33673653






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Investigation of the Impact of CYP3A5 Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens
2 An optimized physiologically-based pharmacokinetic (PBPK) model integrated with CYP3A5 polymorphism was successfully established, providing more insights regarding the long-term DDI between tacrolimus and Wuzhi capsules in patients with different CYP3A5 genotypes. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens
3 An optimized physiologically-based pharmacokinetic (PBPK) model integrated with CYP3A5 polymorphism was successfully established, providing more insights regarding the long-term DDI between tacrolimus and Wuzhi capsules in patients with different CYP3A5 genotypes. Tacrolimus cytochrome P450 family 3 subfamily A member 5 Homo sapiens